Cargando…

Principles of Molecular Oncology

Drawing on years of significant scientific advances and clinical developments, the editors of POMO III have thoroughly updated the highly praised first and second editions and added new chapters to reflect the knowledge emerging from research on genomics, proteomics, chemoprevention strategies, phar...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Bronchud, Miguel H. (Editor ), Foote, MaryAnn (Editor ), Giaccone, Giuseppe (Editor ), Olopade, Olufunmilayo I. (Editor ), Workman, Paul (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Totowa, NJ : Humana Press : Imprint: Humana, 2008.
Edición:3rd ed. 2008.
Temas:
Acceso en línea:Texto Completo

MARC

LEADER 00000nam a22000005i 4500
001 978-1-59745-470-4
003 DE-He213
005 20220114165422.0
007 cr nn 008mamaa
008 100301s2008 xxu| s |||| 0|eng d
020 |a 9781597454704  |9 978-1-59745-470-4 
024 7 |a 10.1007/978-1-59745-470-4  |2 doi 
050 4 |a RC254-282 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
072 7 |a MJCL  |2 thema 
082 0 4 |a 616.994  |2 23 
245 1 0 |a Principles of Molecular Oncology  |h [electronic resource] /  |c edited by Miguel H. Bronchud, MaryAnn Foote, Giuseppe Giaccone, Olufunmilayo I. Olopade, Paul Workman. 
250 |a 3rd ed. 2008. 
264 1 |a Totowa, NJ :  |b Humana Press :  |b Imprint: Humana,  |c 2008. 
300 |a XX, 420 p. 85 illus., 21 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
505 0 |a Selecting the Right Targets for Cancer Therapy -- Clinical Importance of Prognostic Factors -- Genetic Markers in Sporadic Tumors -- Genetic Markers in Breast Tumors with Hereditary Predisposition -- Circulating Tumor Markers -- Antibody-Based Proteomics Analysis of Tumor Cell Signaling Pathways -- Gene Expression Arrays for Pathway Analysis in Cancer Research -- Signaling Pathways in Cancer -- Estrogen Receptor Pathways and Breast Cancer -- Cyclin-Dependent Kinases and Their Regulators as Potential Targets for Anticancer Therapeutics -- Angiogenesis Switch Pathways -- Apoptosis Pathways and New Anticancer Agents -- Genomic Instability, DNA Repair Pathways and Cancer -- Epigenomics and Cancer -- Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well? -- Aurora Kinases: A New Target for Anticancer Drug Development -- Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways -- Suicide Gene Therapy -- Genotypes That Predict Toxicity and Genotypes That Predict Efficacy of Anticancer Drugs -- A Personal Account of the Chemoprevention of Breast Cancer: Possible or Not Possible?. 
520 |a Drawing on years of significant scientific advances and clinical developments, the editors of POMO III have thoroughly updated the highly praised first and second editions and added new chapters to reflect the knowledge emerging from research on genomics, proteomics, chemoprevention strategies, pharmacogenomics, new molecular targets, therapeutic monoclonal antibodies, and innovative cytotoxic and cytostatic small molecular-weight molecules. The first edition of this book (Humana Press, 2000) was also the first comprehensive presentation of the concept of cancer as a "disease process" involving key regulatory pathways. The second edition (2004) reaffirmed this dynamic concept, incorporating more recent evidence, and introducing such new topics of special interest as the combination of molecular diagnostics-expression profiling of genes and proteins- with developmental therapeutics, and the "binary state" concept (active/inactive) that seeks more relevant targets within the global molecular matrix of a given cancer. Comprehensive and intellectually stimulating, POMO III not only clearly elucidates the fundamentals of this dramatically advancing field, but also interprets the vast and often complex molecular data available. It fills a much neglected gap between "information" and "knowledge," and holds out the hope of new anticancer strategies that will reduce the process of carcinogenesis, cancer cell proliferation and significantly reduce metastasis. 
650 0 |a Oncology. 
650 0 |a Hematology. 
650 0 |a Cancer. 
650 0 |a Medicine-Research. 
650 0 |a Biology-Research. 
650 1 4 |a Oncology. 
650 2 4 |a Hematology. 
650 2 4 |a Cancer Biology. 
650 2 4 |a Biomedical Research. 
700 1 |a Bronchud, Miguel H.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Foote, MaryAnn.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Giaccone, Giuseppe.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Olopade, Olufunmilayo I.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Workman, Paul.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9781603277853 
776 0 8 |i Printed edition:  |z 9781934115251 
776 0 8 |i Printed edition:  |z 9781603275057 
856 4 0 |u https://doi.uam.elogim.com/10.1007/978-1-59745-470-4  |z Texto Completo 
912 |a ZDB-2-SME 
912 |a ZDB-2-SXM 
950 |a Medicine (SpringerNature-11650) 
950 |a Medicine (R0) (SpringerNature-43714)